BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Partnership agreement to commercialize new anti-PD1 antibody in Australia and Southeast Asia signed by Specialised Therapeutics

The therapy ANNIKO® (penpulimab) is an anti-PD1 monoclonal antibody currently under regulatory review by the US FDA for nasopharyngeal carcinoma &...

April 12, 2023 | News

JW Therapeutics' Relma-cel approved for systemic lupus erythematosus trial.

SLE is a complex autoimmune disease with diverse clinical manifestations involving many organs and systems. It is estimated that China has 1 mill...

April 11, 2023 | News

Chinese NMPA Approves Study of Telix Brain Cancer Therapy Candidate

The investigational new drug (IND) application was submitted by Telix's partner in the Greater China region, Grand Pharmaceutical Group Limited (...

April 11, 2023 | News

China's First Nectin-4 Targeted ADC 9MW2821 Clinical Progress Released

Developed with site specific conjugate technology, 9MW2821 is China's first, global second Nectin-4 targeted ADC approved for clinical study. The...

April 08, 2023 | News

Metabolon Launches Targeted Panels to Study Microbiome and Gut Metabolome in Health and Disease

Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and pr...

April 05, 2023 | News

Indivumed becomes Indivumed Therapeutics to advance Precision Oncology with Data and AI

After twenty years as one of the first personalized oncology companies, Indivumed today announced its evolution into Indivumed Therapeutics after the acqui...

April 05, 2023 | News

Genome Mapping Takes Center Stage in the Asia Pacific Region

Genome mapping is the process of determining the complete DNA sequence of an organism, including all of its genes and other DNA sequences. The process of g...

April 04, 2023 | Analysis

COVID-19 Infection Shown to Significantly Increase Drug Clearance of Therapeutic Monoclonal Antibodies

Patients with inflammatory diseases being treated with therapeutic monoclonal antibodies (mAbs) such as Infliximab may experience a significant increase in...

April 03, 2023 | News

Athos Therapeutics Receives Regulatory Approval to Commence Phase I Clinical Trial of ATH-063

Athos Therapeutics, Inc. ("Athos"), a clinical stage biotechnology company pioneering the development of artificial intelligence-based precision small mole...

March 30, 2023 | Regulatory

Aptamer Group's Optimer-Fc: An Innovative Solution to Enhance Accuracy of Automated IHC Workflows

Aptamer Group's Chief Technical Officer, Dr David Bunka, speaks to BioPharma APAC about the innovative Optimer-Fc reagent solution for immunohistochemistry...

March 29, 2023 | Influencers

Antengene Doses First Patient with ATG-022 for Advanced Solid Tumors in Australia

Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate (ADC) targeting the Tumor Associated Antig...

March 29, 2023 | News

Thermo Fisher Opens Cell Therapy Facility at UCSF to Advance Breakthrough Therapies.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and the University of California, San Francisco (UCSF), will accelerate adv...

March 28, 2023 | News

Berry Genomics and Ajlan & Bros Holdings Form Joint Venture to Support 'Vision 2030'

The joint venture will focus on genetic testing in the field of reproductive health and carry out in-depth collaboration on a series of projects that lever...

March 28, 2023 | News

BIORCHESTRA Strikes $861M Deal for CNS-Targeted Nanoparticle Delivery of Nucleic Acid Therapies

BIORCHESTRA, a biotherapeutics company focused on the treatment of rare and degenerative diseases within the Central Nervous System (CNS) by leveragin...

March 28, 2023 | News

Stay Connected